Hernando Vargas-Sierra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hernando Vargas-Sierra has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Hernando Vargas-Uricoechea
Metabolic Diseases Study Group, Department of Internal Medicine, University of Cauca, Popayán, Colombia, Colombia
15 shared publications - Alejandro Castellanos-Pinedo
Faculty of Medicine, Universidad del Sinú, Hospital San Jerónimo, Montería 230001, Colombia
13 shared publications - Maria Virginia Pinzon Fernandez
Universidad del Cauca
13 shared publications - Ivonne A. Meza-Cabrera
Metabolic Diseases Study Group, Department of Internal Medicine, Universidad del Cauca, Carrera 6 Nº 13N-50, Popayán 190001, Colombia
7 shared publications - Karen Urrego-Noguera
Metabolic Diseases Study Group, Department of Internal Medicine, Universidad del Cauca, Carrera 6 Nº 13N-50, Popayán 190001, Colombia
7 shared publications - Valentina Agredo-Delgado
Metabolic Diseases Study Group, Department of Internal Medicine, Universidad del Cauca, Carrera 6 Nº 13N-50, Popayán 190001, Colombia
4 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by MDPI AG in Preprints.org
Prevalence and Determinants of Normocalcemic Primary Hyperparathyroidism: A Cross-Sectional Analysis of a Community Cohort
Background/Objectives: Normocalcemic primary hyperparathyroidism (NCPHP), characterized by elevated parathyroid hormone (PTH) and normal calcium, is considered an early phenotype of primary hyperparathyroidism (PHP), but community-based prevalence data are scarce and heterogeneous. The objectives of this study were to determine the prevalence of NCPHP and other phenotypes related to calcium and PTH metabolism, as well as to evaluate potential associated clinical and biochemical variables. Methods: We conducted a cross-sectional analysis of a community cohort of 1,747 adults from urban and rural areas of the Department of Cauca, Colombia, recruited by non-probabilistic sequential sampling. Participants with conditions or medications known to affect calcium-PTH metabolism were excluded. We measured PTH, ionized calcium, 25-hydroxyvitamin D (25OH Vit-D), phosphorus, alkaline phosphatase, and estimated glomerular filtration rate (eGFR), and defined nine phenotypes by cross-tabulating PTH and calcium categories. Predictors of NCPHP were identified with multivariable logistic regression. Results: The median age was 52 years, and 58.2% of participants were women. The prevalence of NCPHP was 9.8% [95% confidence interval (CI): 8.5–11.3], and classic PHP was found in 0.2% (95% CI: 0.1–0.6). In the multivariable model, only older age [adjusted odds ratio (OR): 1.02 per year; 95% CI: 1.01–1.03] and a 25OH Vit-D level Conclusions: In this large, community-based cohort, NCPHP was substantially more prevalent than previously reported, whereas classic PHP remained rare. Older age and vitamin D deficiency were the only independent correlates of the normocalcemic phenotype, findings that warrant confirmation in longitudinal studies.
- 6 November 2026
- Published by MDPI AG in Preprints.org
Open AccessPrevalence and Determinants of Normocalcemic Primary Hyperparathyroidism: A Cross-Sectional Analysis of a Community Cohort
Background/Objectives: Normocalcemic primary hyperparathyroidism (NCPHP), characterized by elevated parathyroid hormone (PTH) and normal calcium, is considered an early phenotype of primary hyperparathyroidism (PHP), but community-based prevalence data are scarce and heterogeneous. The objectives of this study were to determine the prevalence of NCPHP and other phenotypes related to calcium and PTH metabolism, as well as to evaluate potential associated clinical and biochemical variables. Methods: We conducted a cross-sectional analysis of a community cohort of 1,747 adults from urban and rural areas of the Department of Cauca, Colombia, recruited by non-probabilistic sequential sampling. Participants with conditions or medications known to affect calcium-PTH metabolism were excluded. We measured PTH, ionized calcium, 25-hydroxyvitamin D (25OH Vit-D), phosphorus, alkaline phosphatase, and estimated glomerular filtration rate (eGFR), and defined nine phenotypes by cross-tabulating PTH and calcium categories. Predictors of NCPHP were identified with multivariable logistic regression. Results: The median age was 52 years, and 58.2% of participants were women. The prevalence of NCPHP was 9.8% [95% confidence interval (CI): 8.5–11.3], and classic PHP was found in 0.2% (95% CI: 0.1–0.6). In the multivariable model, only older age [adjusted odds ratio (OR): 1.02 per year; 95% CI: 1.01–1.03] and a 25OH Vit-D level Conclusions: In this large, community-based cohort, NCPHP was substantially more prevalent than previously reported, whereas classic PHP remained rare. Older age and vitamin D deficiency were the only independent correlates of the normocalcemic phenotype, findings that warrant confirmation in longitudinal studies.
- Open Access
- 29 October 2026
- Published by MDPI AG in Preprints.org
Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and C-Reactive Protein as Risk Markers in Thyroid Autoimmunity, Hypothyroidism, and Hyperthyroidism: A Cross-Sectional Study
Autoimmune thyroid disease is common, and low-grade systemic inflammation has been proposed as a contributing mechanism. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) are inexpen-sive, widely available inflammatory markers whose value as risk indicators for thyroid autoimmunity and thyroid dysfunction remains incompletely defined. In the present study, we aimed to evaluate whether NLR, PLR, and CRP—alone, combined, and ad-justed for sociodemographic, clinical, habit-related, and laboratory covariates—are associated with thyroid autoimmunity and with alterations in thyroid status. A cross-sectional analysis was conduced in 3,406 adults; participants were measured with TSH, FT4, thyroid antibodies (TRAb, TPOAb, and TgAb), complete blood count, and high-sensitivity CRP values, inter alia. The prevalence of any thyroid status alter-ation was 52.2%, and of thyroid autoimmunity, 39.2%. In multivariable analysis, NLR and PLR were strongly and independently associated with thyroid autoimmunity (both p< 0.001); CRP showed a more modest association (p=0.033). NLR achieved an AUC of 0.752 for autoimmunity. None of the three markers discriminated thyroid status alter-ation overall, but CRP remained independently associated with it and showed a stronger effect within the antibody-positive subgroup. In conclusion, NLR and PLR are robust, independent correlates of thyroid autoimmunity but not of thyroid status al-teration per se, whereas CRP shows a modest but consistent association with both out-comes, particularly in antibody-positive patients. These low-cost markers may com-plement antibody testing for risk stratification in autoimmune thyroid disease.
- 29 October 2026
- Published by MDPI AG in Preprints.org
Open AccessNeutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and C-Reactive Protein as Risk Markers in Thyroid Autoimmunity, Hypothyroidism, and Hyperthyroidism: A Cross-Sectional Study
Autoimmune thyroid disease is common, and low-grade systemic inflammation has been proposed as a contributing mechanism. The neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) are inexpen-sive, widely available inflammatory markers whose value as risk indicators for thyroid autoimmunity and thyroid dysfunction remains incompletely defined. In the present study, we aimed to evaluate whether NLR, PLR, and CRP—alone, combined, and ad-justed for sociodemographic, clinical, habit-related, and laboratory covariates—are associated with thyroid autoimmunity and with alterations in thyroid status. A cross-sectional analysis was conduced in 3,406 adults; participants were measured with TSH, FT4, thyroid antibodies (TRAb, TPOAb, and TgAb), complete blood count, and high-sensitivity CRP values, inter alia. The prevalence of any thyroid status alter-ation was 52.2%, and of thyroid autoimmunity, 39.2%. In multivariable analysis, NLR and PLR were strongly and independently associated with thyroid autoimmunity (both p< 0.001); CRP showed a more modest association (p=0.033). NLR achieved an AUC of 0.752 for autoimmunity. None of the three markers discriminated thyroid status alter-ation overall, but CRP remained independently associated with it and showed a stronger effect within the antibody-positive subgroup. In conclusion, NLR and PLR are robust, independent correlates of thyroid autoimmunity but not of thyroid status al-teration per se, whereas CRP shows a modest but consistent association with both out-comes, particularly in antibody-positive patients. These low-cost markers may com-plement antibody testing for risk stratification in autoimmune thyroid disease.
- 26 October 2026
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Efficacy and Safety of Once-Weekly Basal Insulins versus Once-Daily Basal Insulin Analogues in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis of the ONWARDS and QWINT Phase 3 Clinical Trial Programs
- 26 October 2026
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
Efficacy and Safety of Once-Weekly Basal Insulins versus Once-Daily Basal Insulin Analogues in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis of the ONWARDS and QWINT Phase 3 Clinical Trial Programs
- Open Access
- 18 March 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (1) , 143
Risk of Functional Disorders and/or Thyroid Autoimmunity and Its Association with 25OH Vitamin D and Magnesium Levels: A Population-Based Case-Control Study
Background/Objectives: Vitamin D (Vit-D) and magnesium (Mg) levels have been associated with an increased risk of developing functional thyroid disorders or autoimmune thyroid diseases (AITD). In this study, our objective was to evaluate if 25-hydroxyvitamin D (25OH Vit-D) and/or Mg levels are associated with an increased risk of functional thyroid disorders and/or AITD. Methods: A population-based case-control study was conducted, with a total of 1028 participants (514 cases and 514 controls). Blood concentrations of 25OH Vit-D, Mg, TSH, FT4, FT3, and thyroid autoantibodies (TPOAb, TgAb, and TRAb) were determined in the study participants. Results: Among the cases (in women), the prevalence of goiter, hypothyroidism, and thyroid autoantibody positivity was significantly higher. No differences were found in the prevalence of functional thyroid disorders or in thyroid antibody positivity (among cases) according to sex or age. The prevalence of thyroid antibody positivity (specifically TPOAb and/or TgAb) was significantly higher in cases with 25OH Vit-D and/or Mg deficiency. The 25OH Vit-D level that best discriminated the highest frequency of AITD was 23.5 ng/mL [AUC: 0.665 (95% CI: 0.636–0.694, p < 0.001)]; while for Mg it was 1.8 mg/dL [AUC: 0.697 (95% CI: 0.668–0.725, p < 0.001)], indicating that the model has weak discrimination (although better than chance), with good sensitivity and low specificity, being able to identify the vast majority of positive cases (with AITDs), at the cost of including a significant proportion of false positives. Conclusions: Overall, we found that low serum levels of 25OH Vit-D and/or Mg appear to be associated with a significantly increased risk of goiter, functional thyroid disorders (specifically hypothyroidism), and with greater positivity of thyroid antibodies.
- 18 March 2026
- Published by MDPI AG in Medical Sciences
- Vol. 14 (1) , 143
Open AccessRisk of Functional Disorders and/or Thyroid Autoimmunity and Its Association with 25OH Vitamin D and Magnesium Levels: A Population-Based Case-Control Study
Background/Objectives: Vitamin D (Vit-D) and magnesium (Mg) levels have been associated with an increased risk of developing functional thyroid disorders or autoimmune thyroid diseases (AITD). In this study, our objective was to evaluate if 25-hydroxyvitamin D (25OH Vit-D) and/or Mg levels are associated with an increased risk of functional thyroid disorders and/or AITD. Methods: A population-based case-control study was conducted, with a total of 1028 participants (514 cases and 514 controls). Blood concentrations of 25OH Vit-D, Mg, TSH, FT4, FT3, and thyroid autoantibodies (TPOAb, TgAb, and TRAb) were determined in the study participants. Results: Among the cases (in women), the prevalence of goiter, hypothyroidism, and thyroid autoantibody positivity was significantly higher. No differences were found in the prevalence of functional thyroid disorders or in thyroid antibody positivity (among cases) according to sex or age. The prevalence of thyroid antibody positivity (specifically TPOAb and/or TgAb) was significantly higher in cases with 25OH Vit-D and/or Mg deficiency. The 25OH Vit-D level that best discriminated the highest frequency of AITD was 23.5 ng/mL [AUC: 0.665 (95% CI: 0.636–0.694, p < 0.001)]; while for Mg it was 1.8 mg/dL [AUC: 0.697 (95% CI: 0.668–0.725, p < 0.001)], indicating that the model has weak discrimination (although better than chance), with good sensitivity and low specificity, being able to identify the vast majority of positive cases (with AITDs), at the cost of including a significant proportion of false positives. Conclusions: Overall, we found that low serum levels of 25OH Vit-D and/or Mg appear to be associated with a significantly increased risk of goiter, functional thyroid disorders (specifically hypothyroidism), and with greater positivity of thyroid antibodies.
- Open Access
- 11 February 2026
- Published by MDPI AG in Preprints.org
Risk of Functional Disorders And/or Thyroid Autoimmunity and Its Association with 25OH Vitamin D and Magnesium Levels: A Population-Based Case-Control Study
Background/Objectives: It has been suggested that vitamin D and magnesium levels appear to be associated with an increased risk of functional disorders and/or autoimmune thyroid diseases (AITD). In this study, our objective was to evaluate whether 25OH vitamin D (25OH Vit-D) and/or magnesium (Mg) levels are associated with an increased risk of AITD and/or thyroid dysfunction. Methods: A population-based case-control study was conducted (n = 1028) (cases: n = 514; controls: n = 514). Blood concentrations of 25OH Vit-D, Mg, TSH, FT4, FT3, and thyroid autoantibodies (TPOAb, TgAb, and TRAb) were determined in the study participants. Results: The prevalence of goiter, hypothyroidism, and thyroid autoantibody positivity was significantly higher in women (among cases). No differences were found in the prevalence of other thyroid disorders or thyroid antibody positivity (among cases) based on sex or age. The prevalence of thyroid antibody positivity (specifically TPOAb and/or TgAb) was significantly higher in cases with 25OH Vit-D and/or Mg deficiency. The 25OH Vit-D level that best discriminated the highest frequency of AITD was 23.5 ng/mL [AUC: 0.665 (95% CI: 0.636–0.694, p< 0.001)]; while for Mg it was 1.8 mg/dL [AUC: 0.697 (95% CI: 0.668–0.725, p< 0.001)]. Conclusions: The results of our study suggest that low levels of 25OH Vit-D and/or Mg are associated with an increased risk of goiter, hypothyroidism, and AITD.
- 11 February 2026
- Published by MDPI AG in Preprints.org
Open AccessRisk of Functional Disorders And/or Thyroid Autoimmunity and Its Association with 25OH Vitamin D and Magnesium Levels: A Population-Based Case-Control Study
Background/Objectives: It has been suggested that vitamin D and magnesium levels appear to be associated with an increased risk of functional disorders and/or autoimmune thyroid diseases (AITD). In this study, our objective was to evaluate whether 25OH vitamin D (25OH Vit-D) and/or magnesium (Mg) levels are associated with an increased risk of AITD and/or thyroid dysfunction. Methods: A population-based case-control study was conducted (n = 1028) (cases: n = 514; controls: n = 514). Blood concentrations of 25OH Vit-D, Mg, TSH, FT4, FT3, and thyroid autoantibodies (TPOAb, TgAb, and TRAb) were determined in the study participants. Results: The prevalence of goiter, hypothyroidism, and thyroid autoantibody positivity was significantly higher in women (among cases). No differences were found in the prevalence of other thyroid disorders or thyroid antibody positivity (among cases) based on sex or age. The prevalence of thyroid antibody positivity (specifically TPOAb and/or TgAb) was significantly higher in cases with 25OH Vit-D and/or Mg deficiency. The 25OH Vit-D level that best discriminated the highest frequency of AITD was 23.5 ng/mL [AUC: 0.665 (95% CI: 0.636–0.694, p< 0.001)]; while for Mg it was 1.8 mg/dL [AUC: 0.697 (95% CI: 0.668–0.725, p< 0.001)]. Conclusions: The results of our study suggest that low levels of 25OH Vit-D and/or Mg are associated with an increased risk of goiter, hypothyroidism, and AITD.
- Open Access
- 24 October 2025
- Published by MDPI AG in Medical Sciences
- Vol. 13 (4) , 241
Effectiveness of Selenium Supplementation in the Treatment of Graves–Basedow Disease: A Scoping Review
Background: Graves–Basedow disease (GBD) is an autoimmune thyroid disorder characterized by loss of tolerance to the thyrotropin receptor, with clinical manifestations such as a hyperadrenergic state, goiter, orbitopathy, and myxedema, inter alia. Selenium is a micronutrient, essential for the synthesis of selenoproteins. Selenium deficiency has been linked to an increased risk and exacerbation of GBD and GBD orbitopathy; therefore, it has been suggested that supplementation with this micronutrient could modify some outcomes associated with both conditions. Objectives: The objective of this scoping review was to synthesize and analyze the clinical trials that have evaluated the effectiveness of selenium on different outcomes in patients with GBD or GBD orbitopathy. Methods: The following databases were consulted: PubMed/Medline, Scopus, Biosis, ProQuest, Web of Science, and Google Scholar; and the search terms ‘Graves-Basedow disease’ or ‘Graves’ disease’ or ‘hyperthyroidism’ or ‘Graves’ hyperthyroidism’ or ‘selenium or selenium supplementation’ and ‘effectiveness’ were used. The search was limited to articles published in English between January 2000 and March 2025. To reduce selection bias, each article was reviewed independently by three authors using the Rayyan web tool and the JBI Critical Appraisal Checklist. Results: A total of 15 studies were identified (11 on patients with GBD and 4 on patients with GBD orbitopathy). In GBD, selenium supplementation was associated with significant improvements in TSH, FT4, FT3, TPOAb, TgAb, and TRAb levels; while in GBD orbitopathy, a positive effect of selenium supplementation was found on multiple clinical outcomes. Conclusions: Selenium supplementation in patients with GBD or GBD orbitopathy is associated with favorable biochemical and clinical outcomes.
- 24 October 2025
- Published by MDPI AG in Medical Sciences
- Vol. 13 (4) , 241
Open AccessEffectiveness of Selenium Supplementation in the Treatment of Graves–Basedow Disease: A Scoping Review
Background: Graves–Basedow disease (GBD) is an autoimmune thyroid disorder characterized by loss of tolerance to the thyrotropin receptor, with clinical manifestations such as a hyperadrenergic state, goiter, orbitopathy, and myxedema, inter alia. Selenium is a micronutrient, essential for the synthesis of selenoproteins. Selenium deficiency has been linked to an increased risk and exacerbation of GBD and GBD orbitopathy; therefore, it has been suggested that supplementation with this micronutrient could modify some outcomes associated with both conditions. Objectives: The objective of this scoping review was to synthesize and analyze the clinical trials that have evaluated the effectiveness of selenium on different outcomes in patients with GBD or GBD orbitopathy. Methods: The following databases were consulted: PubMed/Medline, Scopus, Biosis, ProQuest, Web of Science, and Google Scholar; and the search terms ‘Graves-Basedow disease’ or ‘Graves’ disease’ or ‘hyperthyroidism’ or ‘Graves’ hyperthyroidism’ or ‘selenium or selenium supplementation’ and ‘effectiveness’ were used. The search was limited to articles published in English between January 2000 and March 2025. To reduce selection bias, each article was reviewed independently by three authors using the Rayyan web tool and the JBI Critical Appraisal Checklist. Results: A total of 15 studies were identified (11 on patients with GBD and 4 on patients with GBD orbitopathy). In GBD, selenium supplementation was associated with significant improvements in TSH, FT4, FT3, TPOAb, TgAb, and TRAb levels; while in GBD orbitopathy, a positive effect of selenium supplementation was found on multiple clinical outcomes. Conclusions: Selenium supplementation in patients with GBD or GBD orbitopathy is associated with favorable biochemical and clinical outcomes.
- Open Access
- 16 September 2025
- Published by MDPI AG in Preprints.org
Effectiveness of Selenium Supplementation in the Treatment of Graves–Basedow Disease. A Scoping Review
Graves-Basedow disease (GBD) is an autoimmune thyroid disorder characterized by loss of tolerance to the thyrotropin receptor, with clinical manifestations such as a hyperadrenergic state, goiter, orbitopathy, and myxedema, among others. Selenium is a micronutrient, essential for the synthesis of selenoproteins. Selenium deficiency has been linked to an increased risk and exacerbation of GBD and GBD orbitopathy; therefore, it has been suggested that supplementation with this micronutrient could modify some outcomes associated with both conditions. Methods and results: The objective of this scoping review was to synthesize and analyze the clinical trials that have evaluated the effectiveness of selenium on different outcomes in patients with GBD or GBD orbitopathy. The following databases were consulted: PubMed/Medline, Scopus, Biosis, ProQuest, Web of Science, and Google Scholar, and the search terms ‘Graves-Basedow disease’ or ‘Graves' disease’ or ‘hyperthyroidism’ or ‘Graves' hyperthyroidism’ or ‘selenium or selenium supplementation’ and ‘effectiveness’ were used. The search was limited to articles published in English between January 2000 and March 2025. To reduce selection bias, each article was reviewed independently by three authors using the Rayyan web tool and the JBI Critical Appraisal Checklist. A total of 15 studies were identified (11 in patients with GBD and 4 in patients with GBD orbitopathy). In GBD, selenium supplementation was associated with significant improvements in TSH, FT4, FT3, TPOAb, TgAb, and TRAb levels; while in GBD orbitopathy, a positive effect of selenium supplementation was found on multiple clinical outcomes. Conclusions: Selenium supplementation in patients with GBD or GBD orbitopathy is associated with favorable biochemical and clinical outcomes.
- 16 September 2025
- Published by MDPI AG in Preprints.org
Open AccessEffectiveness of Selenium Supplementation in the Treatment of Graves–Basedow Disease. A Scoping Review
Graves-Basedow disease (GBD) is an autoimmune thyroid disorder characterized by loss of tolerance to the thyrotropin receptor, with clinical manifestations such as a hyperadrenergic state, goiter, orbitopathy, and myxedema, among others. Selenium is a micronutrient, essential for the synthesis of selenoproteins. Selenium deficiency has been linked to an increased risk and exacerbation of GBD and GBD orbitopathy; therefore, it has been suggested that supplementation with this micronutrient could modify some outcomes associated with both conditions. Methods and results: The objective of this scoping review was to synthesize and analyze the clinical trials that have evaluated the effectiveness of selenium on different outcomes in patients with GBD or GBD orbitopathy. The following databases were consulted: PubMed/Medline, Scopus, Biosis, ProQuest, Web of Science, and Google Scholar, and the search terms ‘Graves-Basedow disease’ or ‘Graves' disease’ or ‘hyperthyroidism’ or ‘Graves' hyperthyroidism’ or ‘selenium or selenium supplementation’ and ‘effectiveness’ were used. The search was limited to articles published in English between January 2000 and March 2025. To reduce selection bias, each article was reviewed independently by three authors using the Rayyan web tool and the JBI Critical Appraisal Checklist. A total of 15 studies were identified (11 in patients with GBD and 4 in patients with GBD orbitopathy). In GBD, selenium supplementation was associated with significant improvements in TSH, FT4, FT3, TPOAb, TgAb, and TRAb levels; while in GBD orbitopathy, a positive effect of selenium supplementation was found on multiple clinical outcomes. Conclusions: Selenium supplementation in patients with GBD or GBD orbitopathy is associated with favorable biochemical and clinical outcomes.
- Open Access
Iodine Intake from Universal Salt Iodization Programs and Hashimoto’s Thyroiditis: A Systematic Review
Background: Hashimoto’s thyroiditis (HT) is characterized by the loss of tolerance to thyroid autoantigens [thyroid peroxidase (TPO) and thyroglobulin (Tg)], usually identifying circulating antibodies (Abs) against these thyroid autoantigens (TPOAb and/or TgAb), together with a significant lymphocytic infiltration, causing an increased risk of hypothyroidism. Among the multiple mechanisms described for the development of HT is the nutritional status of several micronutrients, including iodine. Iodine deficiency or excess is associated with thyroid function disorders and, likely, thyroid autoimmunity. Thus, iodized salt intake [especially through universal salt iodization (USI) programs] may be influencing the prevalence of HT. The objectives of this systematic review are to describe and analyze changes over time in the prevalence of HT following the implementation of USI programs. Methods and results: The following databases were consulted for articles published from January 1965 to January 2025: Pubmed/Medline; ProQuest; Scopus; Biosis; Web of Science; and Google Scholar. The search terms were as follows: “iodine”, “salt”, “intake”, “prevalence”, AND Hashimoto’s thyroiditis. Only English language articles were taken into account, and each of them was scrutinized according to the JBI Critical Appraisal Checklist. Only those studies in which the design, study population, number of participants, country, evaluation post-USI (years), and the prevalence of thyroid Abs positivity were described were included. In total, 74 studies were identified, of which 31 evaluated thyroid Abs values post-USI. Conclusions: Excess iodine intake, mediated by USI programs without an adequate follow-up and monitoring plan, may explain (at least in part) the prevalence and distribution of HT; therefore, it is a real challenge to establish a balance between healthy salt intake, USI program strategies, and possible functional outcomes and thyroid autoimmunity in the population. Registration number: INPLASY202540074.
Open AccessIodine Intake from Universal Salt Iodization Programs and Hashimoto’s Thyroiditis: A Systematic Review
Background: Hashimoto’s thyroiditis (HT) is characterized by the loss of tolerance to thyroid autoantigens [thyroid peroxidase (TPO) and thyroglobulin (Tg)], usually identifying circulating antibodies (Abs) against these thyroid autoantigens (TPOAb and/or TgAb), together with a significant lymphocytic infiltration, causing an increased risk of hypothyroidism. Among the multiple mechanisms described for the development of HT is the nutritional status of several micronutrients, including iodine. Iodine deficiency or excess is associated with thyroid function disorders and, likely, thyroid autoimmunity. Thus, iodized salt intake [especially through universal salt iodization (USI) programs] may be influencing the prevalence of HT. The objectives of this systematic review are to describe and analyze changes over time in the prevalence of HT following the implementation of USI programs. Methods and results: The following databases were consulted for articles published from January 1965 to January 2025: Pubmed/Medline; ProQuest; Scopus; Biosis; Web of Science; and Google Scholar. The search terms were as follows: “iodine”, “salt”, “intake”, “prevalence”, AND Hashimoto’s thyroiditis. Only English language articles were taken into account, and each of them was scrutinized according to the JBI Critical Appraisal Checklist. Only those studies in which the design, study population, number of participants, country, evaluation post-USI (years), and the prevalence of thyroid Abs positivity were described were included. In total, 74 studies were identified, of which 31 evaluated thyroid Abs values post-USI. Conclusions: Excess iodine intake, mediated by USI programs without an adequate follow-up and monitoring plan, may explain (at least in part) the prevalence and distribution of HT; therefore, it is a real challenge to establish a balance between healthy salt intake, USI program strategies, and possible functional outcomes and thyroid autoimmunity in the population. Registration number: INPLASY202540074.